Fig. 1From: A window-of-opportunity trial of the CXCR1/2 inhibitor reparixin in operable HER-2-negative breast cancerMean total reparixin concentration versus time on day 1 (line with circles) and 21 (line with triangles). Results are presented as mean ± SEMBack to article page
